Form 4: Pliant Therapeutics Director Suzanne Bruhn Acquires 26,764 Stock Options

Director Suzanne Bruhn acquired 26,764 stock options in Pliant Therapeutics on June 13, 2024, at an exercise price of $13.06.

Summary

• On June 13, 2024, Suzanne Louise Bruhn, a director of Pliant Therapeutics, acquired 26,764 options to buy common stock.
• The exercise price for these options is $13.06.
• The options vest quarterly, with 25% vesting on the first day of each calendar quarter for three quarters following the grant date.
• The remaining 25% vests on the earlier of the one-year anniversary of the grant date or the next annual meeting of stockholders, contingent on continued service as a director.
• Following the transaction, Ms. Bruhn directly owns 26,764 shares of Pliant Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing, indicating a neutral sentiment. It reflects standard compensation practices.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests between management and shareholders.

Comparison to Industry Standards

• Director stock option grants are a common form of compensation in the biotechnology industry, aligning director interests with company performance.
• The vesting schedule described is fairly standard, promoting long-term commitment from the director.

Stakeholder Impact

• The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's long-term success.

Key Dates